A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: A Report from the Children's Oncology Group

BACKGROUND: This Phase 2 study tested the tolerability and efficacy of bortezomib combined with reinduction chemotherapy for pediatric patients with relapsed, refractory or secondary acute myeloid leukemia (AML). Correlative studies measured putative AML leukemia initiating cells (AML-LIC) before an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Horton, Terzah M., Perentesis, John P., Gamis, Alan S., Alonzo, Todd A., Gerbing, Robert B., Ballard, Jennifer, Adlard, Kathleen, Howard, Dianna S., Smith, Franklin O., Jenkins, Gaye, Kelder, Angelé, Schuurhuis, Gerrit J., Moscow, Jeffrey A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4247259/
https://ncbi.nlm.nih.gov/pubmed/24976003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25117
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados